Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process

Retrovirology

Volumn 14, Issue 1, 2017, Pages

  Gonzalez, Mileidy ^a   DeVico, Anthony L ^b   Spouge, John L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Phenotypic versus genotypic selection; Selection during HIV transmission; T F; Transmission signatures; Transmitted founder virus

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; STOCHASTIC MODEL; SWISS; ANIMAL; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANIMALS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS;

EID: 85013742100     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-016-0326-1     Document Type: Letter

References (17)

1. Oberle CS, et al. Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology. 2016;13(1):62.
2. Gnanakaran S, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7(9):e1002209.
3. Gonzalez MW, et al. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission. J Virol. 2015;89(7):3619-29.
4. Smith SA, et al. Signatures in Simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques. J Virol. 2016;90(4):1880-7.
5. Keele BF, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med. 2009;206(5):1117-34.
6. Roederer M, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505(7484):502-8.
7. Baalwa J, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436(1):33-48.
8. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-93.
9. Rolland M, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17(3):366-71.
10. Nduati R, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283(9):1167-74.
11. Wu X, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80(2):835-44.
12. Salazar-Gonzalez JF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273-89.
13. Klein K, et al. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol. 2013;87(21):11604-16.
14. Santra S, et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 2015;11(8):e1005042.
15. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
16. Crooks GE, et al. WebLogo: a sequence logo generator. Genome Res. 2004;14(6):1188-90.
17. Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18(20):6097-100.